Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in Phase II for Carcinoid Syndrome (Malignant Carcinoid Syndrome). According to GlobalData, Phase II drugs for Carcinoid Syndrome (Malignant Carcinoid Syndrome) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paltusotine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paltusotine hydrochloride overview
Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and neuroendocrine tumors, carcinoid syndfrome. The drug candidate is administered through oral route. The drug candidate is a biased nonpeptide acts by targeting somatostatin receptor. The drug candidate was under development for age-related macular degeneration (AMD) and diabetic retinopathy.
Crinetics Pharmaceuticals overview
Crinetics Pharmaceuticals (Crinetics) is a pharmaceutical company. It developes of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products portfolio comprises paltusotine (Oral SST2 agonist); CRN04777 (SST5 agonist); and CRN04894 (ACTH agonist). It provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.
For a complete picture of Paltusotine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.